Articles tagged with Pancreatic Cancer
Researchers at Cardiff University have secured a £2M MRC Programme Grant to investigate the potential of a calcium-like molecule in protecting against enzymes that trigger pancreatitis. The team aims to better understand stellate cells, which may be the link between chronic pancreatitis and pancreatic cancer.
Researchers have identified mutations in the ATM gene as a potential risk factor for increased pancreatic cancer risk. Studies found that ATM gene mutations were present in four of 166 patients with pancreatic cancer, but absent in healthy spousal controls.
Scientists at Thomas Jefferson University's Center for Translational Medicine have found that reducing N-cadherin levels in pancreatic cancer cells can slow down their mobility and prolong survival in mice by 25 percent. This discovery could lead to new targeted therapies for pancreatic cancer.
Research found that patients with high levels of nickel and selenium had a lower risk of pancreatic cancer, whereas those with high levels of lead, arsenic, and cadmium had an increased risk. These findings suggest a potential role of trace elements in pancreatic carcinogenesis.
Researchers at IRB Barcelona have discovered a new genetic program that converts epithelial cells into mobile invasive cells, which is common in embryonic development and tumour progression. The GATA6 gene plays a key role in this process, triggering survival factors and degrading the cellular matrix to facilitate cell migration.
The RTOG is launching a phase I trial testing ganitumab for locally advanced pancreatic cancer. The trial will investigate the safety and efficacy of ganitumab when combined with chemoradiation treatment. By targeting the IGF-1R pathway, ganitumab may offer a new approach to treating this aggressive form of cancer.
Researchers developed two new QCancer algorithms to predict patients most likely to have pancreatic and bowel cancer, improving early diagnosis and treatment options. The calculators were successful in predicting 62% of pancreatic cancers and 70% of bowel cancers diagnosed over the following two years.
Scientists developed a vaccine that reduces tumors by 80% in mouse models of breast and pancreatic cancer. The vaccine uses a unique carbohydrate signature to train the immune system to target cancer cells.
The 'Seena I' clinical trial aims to find a cure for pancreatic cancer by attacking all components of the tumor. The trials are supervised by the Pancreatic Cancer Research Team and involve four clinical sites across the nation.
Researchers have discovered that connexin 36 protects mouse pancreatic beta-cells against immune molecules prevalent in type 1 diabetes. Additionally, a study found that PTHrP drives breast tumor initiation, progression, and metastasis in mice, suggesting it as a potential therapy target.
A study published in Gut found that specific types of mouth bacteria are associated with pancreatic cancer. The researchers identified two key species - Neisseria elongata and Streptococcus mitis - which were significantly less present in cancer patients' mouths, while Granulicatella adjacens levels were higher.
A new drug combination of gemcitabine and nab-paclitaxel has shown impressive results in a clinical trial for patients with advanced pancreatic cancer. The study, led by Dr. Daniel Von Hoff, found that about half the patients showed reductions in tumor size and about 50 percent lived at least a year.
The study reveals that EGFR plays a crucial role in the development of KRAS-driven pancreatic cancer, blocking its progression without it. Researchers found that mice with EGF receptor deletion had blocked pancreatic cancer development.
Masaaki Tamura's team creates a targeted therapy to combat lung cancer by delivering a receptor gene to cancer cells via nanoparticles, stimulating the immune system to prevent tumor growth. The therapy uses a cationic peptide to guide the gene to cancerous cells, offering a non-invasive treatment option for lung cancer patients.
Mattress Firm Foundation is committed to raising awareness and funding for TGen's globalCure clinical trials, focusing on funding research and clinical trials. The company has already raised over $400,000 through employee donation programs and online fundraising platforms.
A prospective cohort study found that a tumor marker and targeted endoscopic ultrasound can detect stage 1 pancreatic cancer in high-risk populations more effectively than standard means of detection. The study identified a total of one patient with stage 1 disease among 546 enrolled participants.
Scientists developed a gene-based test to identify precancerous pancreatic cysts, which can help patients avoid unnecessary surgeries. The test found mutations in KRAS and GNAS genes, associated with pancreatic cancer, but not in benign cysts.
Researchers at Johns Hopkins have identified two genes, ATRX and DAXX, that contribute to the lengthening of telomeres in cancer cells. The study found a correlation between mutations in these genes and alternative lengthening of telomeres in various types of tumors.
Researchers at Mayo Clinic have found a reliable method to detect pancreatic cancer through DNA testing of stool samples, with a marker detecting methylated genes in 70% of patients. This noninvasive test may lead to increased early detection and improved survival rates for those diagnosed with the disease.
Researchers have successfully used oncolytic viruses to infect and kill pancreatic cancer stem cells, which are thought to cause disease recurrence and metastasis. This breakthrough could provide a potential therapy for pancreatic cancer patients, particularly those with tumors resistant to conventional chemotherapy and radiation.
Researchers have identified a protein in blood serum that distinguishes pancreatic cancer from non-cancerous conditions. The discovery suggests a potential blood test to detect pancreatic cancer at an earlier stage.
A group of Ohio greenhouse growers partners with the Translational Genomics Research Institute to sell 'denim shock wave petunias' in support of pancreatic cancer awareness. The program aims to raise funds for TGen's globalCure initiative, which seeks to find a cure for pancreatic cancer.
Researchers at UCSF have discovered a link between inflammation and the early formation of pancreatic cancer. They found that two molecular signals produced in the pancreas during inflammation can help initiate the early stages of cancer, while another protein may be a clinical indicator of cancer stage.
Mattress Firm has named Translational Genomics Research Institute as its charitable partner of choice to support globalCure's fight against pancreatic cancer. The company will donate $50 to globalCure for every Simmons Beautyrest dual floor sample sold nationwide, aiming to raise over $100,000.
NYU School of Medicine researcher Cosimo Commisso will receive a grant to investigate the role of fluid uptake in pancreatic cancer cells. The goal is to understand how this process contributes to tumor development and identify potential targeting strategies.
A large case-control study found that taking aspirin at least once a month can reduce the risk of pancreatic cancer by 26% compared to non-users. The effect was also seen in those taking low-dose aspirin for heart disease prevention, with a 35% lower risk.
The Pancreatic Cancer Action Network and the American Association for Cancer Research awarded 10 grants totaling nearly $3 million to support innovative pancreatic cancer research. The recipients will be honored at the AACR Annual Meeting, with a focus on building a comprehensive and coordinated pancreatic cancer research community.
The Pancreatic Cancer Action Network and AACR have awarded Jennifer M. Bailey and E. Scott Seeley $600,000 grants to pursue groundbreaking research on pancreatic cancer initiation and progression. Their projects focus on novel insights into KRAS mutations and transport proteins as modifiers of oncogenic signaling.
Researchers at the University of Pennsylvania have discovered a novel way to treat pancreatic cancer by activating the immune system to destroy the cancer's scaffolding. The strategy was tested in a small cohort of patients with advanced pancreatic cancer, resulting in substantial tumor shrinkage and reduced metabolic activity.
A Cardiff University-led study has discovered a protein, calmodulin, that protects pancreatic cells against the harmful effects of alcohol. The findings could lead to the development of new treatments for pancreatitis and reduce the risk of pancreatic cancer.
Researchers at Dana-Farber Cancer Institute have found that a malaria drug, hydroxychloroquine, can slow the growth of pancreatic tumors in mice. The oral drug has been shown to decrease tumor growth by inhibiting autophagy, a survival strategy used by cancer cells.
A long-term study found that consuming three or more drinks a day is associated with an increased risk of pancreatic cancer death in both men and women. Heavy drinking, specifically liquor consumption, also shows a significant association with pancreatic cancer mortality, particularly among never smokers.
A University of Georgia research team found that modifying a cell-surface protein called CNT1 can increase the effectiveness of gemcitabine, a common drug used to treat pancreatic cancer. By improving CNT1 function, researchers can help carry the drug into tumor cells and prevent proliferation.
Researchers identified specific genetic mutations that predict tumor aggressiveness and treatment response in patients with neuroendocrine pancreatic cancer. The study's findings could lead to personalized cancer therapy and improved patient outcomes.
A team of researchers has made a discovery about how the Ras oncogene chooses a signaling pathway and its consequences in cellular development, a key issue in cancer. The study used a common roundworm, C. elegans, to identify the critical events leading to pancreatic cancer.
A study published in Science reveals that satellite repeats, previously thought to be inactive, are actively expressed in many types of epithelial cancers. This discovery may lead to the development of a new cancer biomarker for early detection and improved understanding of tumor behavior.
Researchers at The Peggy and Charles Stephenson Oklahoma Cancer Center have found a way to stop early stage pancreatic cancer in research models, offering a promising approach for high-risk patients. A clinical trial has been launched, and the FDA-approved drug Gefitinib is expected to be tested nationwide within a year.
The 2010 Golf Atlanta charity golf tournament raised $105,000 to support investigations into pancreatic cancer at The Translational Genomics Research Institute. The event drew 124 players and included a high-end auction with donations supporting TGen's life-changing research.
Researchers at Thomas Jefferson University have been awarded a $100,000 grant from the W.W. Smith Charitable Trust to investigate why African-Americans respond poorly to common chemotherapeutic agents used to treat pancreatic cancer.
A study published in Cancer Prevention Research found that gefitinib reduced pancreatic tumor incidence by 77% in mid-dose group and 100% in high-dose group. The compound also showed potential in preventing precursor lesions, with 67.6% of mice free of pancreatic intraepithelial neoplasms at 100 ppm dose.
A UNC research team has identified RGL2 as a critical protein in the KRAS signaling pathway, which could lead to the development of effective pancreatic cancer treatments. The team's findings suggest that blocking this pathway may hold promise for halting the growth of pancreatic tumors.
Researchers at Henry Ford Hospital found stereotactic body radiotherapy (SBRT) to be an effective treatment option for inoperable pancreatic cancer patients, slowing disease progression by almost six months. SBRT provides a highly targeted cancer radiation therapy with minimal side effects.
Researchers uncovered unique genomic instability in pancreatic cancer, which drives tumor adaptation and spread. This study highlights the need for improved early diagnosis methods and targeted treatments.
A new study from Johns Hopkins Medicine finds that pancreatic cancers develop and spread much more slowly than previously thought. The research suggests that there is a potentially broad window for diagnosis and prevention of the disease, with an average progression time of 11.7 years.
A project led by Mr Hemant Kocher aims to target the stroma surrounding pancreatic cancer tumours, which is believed to drive tumour growth and prevent drug treatments from reaching the tumour. The research may lead to new drug targets for treating pancreatic cancer, a disease with poor survival rates.
Researchers at Rice University are testing a nanoparticle designed to diagnose and treat pancreatic cancer, which is notoriously difficult to treat with a five-year preclinical testing program funded by the National Cancer Institute.
A team of UNC scientists has received a $2,308,800 grant to develop targeted nano-particle technology for early detection and more effective treatments of pancreatic cancer. The goal is to design nanoscale metal-organic frameworks capable of carrying imaging and therapeutic cargoes or multiple drugs.
A study found that nearly three-quarters of pancreatic cancer tumours have high levels of a protein called P110γ, which could provide a new target for treatments. Blocking this protein stopped cancer cell growth in laboratory experiments.
A study published in JAMA found that gemcitabine was not superior to fluorouracil plus folinic acid in terms of overall survival for patients with resected pancreatic cancer. The study included 1,088 patients and showed no significant difference in survival estimates between the treatment groups.
A study by UCLA researchers found that pancreatic cancer cells can metabolize fructose to generate nucleic acids, driving cell division and proliferation. The study suggests that high fructose corn syrup consumption may be linked to increased cancer risk, highlighting the need for reduced refined sugar intake.
Researchers developed functional magnetic resonance imaging (MRI) to evaluate pancreatic cancer models, using diffusion-weighted and transcatheter intraarterial perfusion MRI to differentiate living from dead cells. This non-invasive method may replace invasive techniques like biopsy or necropsy for assessing therapeutic efficacy.
A six-gene signature associated with metastatic disease has been identified in patients with pancreatic cancer, enabling earlier prediction of survival prognosis and potential therapeutic targets. This finding may inform treatment decisions and improve patient outcomes.
A new study finds that endoscopic ultrasound (EUS) is associated with improved outcomes in patients with localized pancreatic cancer. EUS evaluation was found to improve overall survival, possibly due to earlier cancer detection and more selective surgery. The study analyzed a large population-based cancer registry and demonstrated the...
Researchers at Heidelberg University Hospital found a promising new treatment for pancreatic cancer combining sorafenib with sulforaphane, an anti-cancer compound in broccoli. The combination treatment inhibits resistant tumor stem cells and blocks metastasis without causing additional side effects.
Pancreatic researchers have developed a method to distinguish between pre-cancerous and benign cysts using glycans. This could lead to fewer deaths from pancreatic cancer by detecting and removing pre-cancerous cysts. The study's findings offer new hope for early detection and treatment of the disease.
Researchers at the University of Pennsylvania School of Medicine have made significant progress in treating metastatic breast cancer, using a targeted immunotherapy approach that boosts the effectiveness of a therapeutic vaccine. The treatment has shown rapid and marked loss of Tregs without toxicity, resulting in stabilization of dise...
Researchers found that patients with pancreatic adenocarcinoma whose tumors respond most to preoperative chemotherapy and radiation survive four times as long, on average, than those who respond least. The study suggests that identifying molecular factors associated with a major pathologic response could lead to important progress in t...
Researchers found that pancreatic cancer patients with circulating tumor cells tend to have worse outcomes, and some types of cells may predict poorer survival. The presence of MUC1 protein-expressing circulating tumor cells is particularly associated with shorter overall survival.
Research from UT Southwestern Medical Center found that heavy alcohol use and binge drinking significantly increase the risk of pancreatic cancer in men. Men who consumed large amounts of alcohol were up to 6 times more likely to develop pancreatic cancer compared to those who drank little or no alcohol.
Researchers confirm a link between pancreatic cancer and inflammatory bowel disease, finding that EUS is as effective as surgery in treating pancreatic pseudocysts. Additionally, studies suggest that intra-abdominal fat can predict survival in pancreatic cancer patients, while new technology shows promise for improved surgical procedures.